Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Atrial fibrillation--frequency control or cardioversion?].

H Volkmann1

  • 1Erzgebirgsklinikum Annaberg, Klinik für Innere Medizin, Chemnitzer Strasse 15, 09456 Annaberg-Buchholz.

Zeitschrift Fur Kardiologie
|January 11, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[From loss of consciousness to syncope].

Herzschrittmachertherapie & Elektrophysiologie·2011
Same author

Ernst abbe and his work.

Applied optics·2010
Same author

[Antithrombotic therapy in atrial fibrillation: when vitamin K antagonists? When aspirin? When heparin? When combinations of anticoagulant and antiplatelet drugs?].

Herzschrittmachertherapie & Elektrophysiologie·2009
Same author

Antibiotic resistant pathogenic bacteria and their resistance genes in bacterial biofilms.

The International journal of artificial organs·2006
Same author

[Cardiac resynchronization therapy: who is suitable? Who requires an additional ICD as a backup?].

Zeitschrift fur Kardiologie·2006
Same author

[On alternative therapy].

Ugeskrift for laeger·1999
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[On pathogenesis of coronary heart disease].

Zeitschrift fur Kardiologie·2016
Same journal

An overview of the evolution of the atherosclerotic plaque: from fatty streak to plaque rupture and thrombosis.

Zeitschrift fur Kardiologie·2016
Same journal

[Not Available].

Zeitschrift fur Kardiologie·2016
Same journal

[Reconstructive surgery of the aortic root].

Zeitschrift fur Kardiologie·2016
See all related articles

Treatment for atrial fibrillation often relies on empirical methods rather than clinical trial data. Current therapy strategies for atrial fibrillation are individualized, prioritizing patient symptoms and the "do no harm" principle.

Area of Science:

  • Cardiology
  • Clinical Electrophysiology

Background:

  • Atrial fibrillation is the most prevalent clinical arrhythmia requiring treatment.
  • Current therapeutic principles for atrial fibrillation are largely empirical, lacking robust clinical trial evidence.
  • There is insufficient scientific data to guide recommendations between cardioversion and rate control strategies.

Purpose of the Study:

  • To address the lack of evidence-based guidelines for atrial fibrillation management.
  • To investigate the optimal therapeutic strategy: cardioversion versus rate control.
  • To inform clinical decision-making in the absence of definitive trial results.

Main Methods:

  • Randomized clinical trials are currently underway to compare cardioversion and rate control.
  • Therapeutic decisions are currently made on a case-by-case basis.

Related Experiment Videos

  • Patient-reported symptoms and the principle of "nihil nocere" (do no harm) are primary considerations.

    • Main Results:

    • Definitive results from ongoing randomized clinical trials are not expected before the year 2000.
    • Individualized treatment strategies are currently employed.
    • Patient complaints and the "do no harm" principle guide current therapeutic choices.

    Conclusions:

    • The optimal management strategy for atrial fibrillation (cardioversion vs. rate control) remains undetermined by definitive clinical trial data.
    • Current clinical practice relies on empirical approaches and individual patient assessment.
    • Future randomized trials are crucial for establishing evidence-based guidelines for atrial fibrillation therapy.